Previous close | 1.6700 |
Open | 2.4300 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 165.00 |
Expiry date | 2024-07-19 |
Day's range | 1.3600 - 2.5000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.